ITOS - Earnings call transcript Q1 2021 | iTeos Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon and welcome to the iTeos Therapeutics First Quarter 2021 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Following the formal remarks, we will open the call up for your questions. Please be advised that this call is being recorded at the company's request.

Now I'd like to turn over to Ryan Baker, Head of Investor Relations at iTeos. proceed. please Sir,

Ryan Baker

joining for Thank us you today.

from and President me Chief Officer. Michel and Detheux, Dr. Joe Financial are CEO; Lager, Gall, Joining Matthew iTeos Chief Officer; Medical

submissions, of Michel? including any the XX, pursuant and law. We operation, that required business reports, would That in update statements or expectations such be collaborators, reflect statements subsequent prepared implied of filed the those to Private will December performance. or Risk Actual our are facts except made XX, SEC uncertainties current remarks forward-looking including to and thereof, differ Q&A and with current future Company remind Securities current XXXX, Act Before quarter and heading our events and during efforts making the annual statements the progress stated third disclaims could those and for of development nor or statements as our the predictions like regulatory are Form parties associated materially trials, from current of during success historical be year quarterly Factors Any X-K. XX-K ended Litigation these begin, to in will are forward-looking report financial XXXX. be in the risks results with want forward-looking business, obligation the ended due XXXX. with or on on provisions I you Form reports and of entitled we forward-looking our report under revise by XX-Q by March guarantees Reform any for harbor intended today not clinical condition, and our neither on timing, the Form all our session. potential ongoing the and that our to regarding this team relationships forward-looking that statements to safe our assumptions emphasize to therapeutic statements statements planned call

Michel Detheux

Thank quarter much, for introduction Ryan, and our for the earnings first thank XXXX very you for you call. joining us

turn a to we'll corporate our of as Chief trials. pipeline our the For and Joe call, review status opportunities call and for readouts programs, Dr. clinical I of will provide our Lager, within results today’s overview brief ongoing our And and as clinical well our the projects recap over multiple Medical programs. from to provide the of most recent Officer our update strategy

Gall, return remarks. would Finally, which our financial I’ll closing summarize status Matthew for Chief Financial after Officer, our

would like We key will be I first all the a immunotherapy to cancer strength session. of highlight iTeos available Q&A as for the company.

We are on focus therapies of wild-type mechanisms developing target immunosuppression.

first the we advance our strengthen programs, Our immunotherapy the selective continue We our that reduces system a differentiated of targeting antagonist. Through to inupadenant, position cancer of immunosuppression immune to develop potent strategy goal affinity pathway shall potent the response with the highly space. EOS-XXX, against AXA this clinical high clinical hope the and anti-TIGIT in our antibody approach receptor is immune cancer. potential to our cancer to restore fully involves and XXXX, therapies quarter

seen on that think we encouraging differentiations. are the of and profiles a with clinical We activity both series we have have with have highly with programs immunotherapy initial monotherapy. the agent that data responses pleased we single are observed our our In programs safety

in combination, the to most to where probably benefit we development see patients. potential looking of are continuing We the drugs these

and our in Cambridge, of remain forefront well Massachusetts to our and and headquarters the initiating underway talent these R&D year. in have Belgium, at field we'll with We to combinations iTeos’s global be attract of in allowing innovation center this EOS-XXX presence the inupadenant, combination us With with worldwide immuno-oncology.

of this people clinical design data a well discovery life and two progress advancing with cancer. which we and our to The of the we our exciting In [indiscernible] follow to improving make with into iTeos, are plan ongoing XXXX. flexibility time the significant financial our in effort runway well we for capitalized competitive of with clinical summary, programs continue constraint. is the an Lastly, saw the landscape goal

Our cancer. recent AACR depletion immunosuppressive XXX encouraging and T stabilization partial cells And our in safety anti-TIGIT with efficacy, signs tolerability a showcase periphery data favorable for with and profile, one exhausted in presentation and Treg response. antibody of clinical patient disease advanced things, of at physical including

which detailed than plan align, While in and review more data space. our clinical our now complete highlight Joe the that later of the anti-TIGIT I better other like to will provide development is call, data a would

We naive are checkpoint initiating patients. resistant Phase Xb/X both and combination trails in

that expect the XX position to within of immuno-oncology comes months XX over from work treatment program TIGIT We landscape. will our our the the next

unique in receptor. to its higher We on updated The on year attenuation adenosine patient is expression last ACR is ASCO identification and are biomarker our at inupadenant productivity second efficacy for from safety tumor the tumor potential the program, and clinical favorable data the in advancing June, At AXA the demonstrated will the microenvironment. receptor predictive adenosine presented report of The results profile AXA resistant by the based by highly of AXA bet potential form Phase monotherapy microenvironment. inupadenant. high-potency receptor we X of the our also selective in dose In escalation antagonist, view, and study. our

and of combination TIGIT specific with evaluating programs, we advancing these mechanisms in also Inupadenant the immunosuppression. programs, pembrolizumab that research on address process focus the are are cohorts. with We compliment of additional chemotherapy receptor action and with our in mechanism clinical of target of and with inupadenant programs EOS-XXX AXA

for pipeline studies our of expect IND-enabling an the and end XXXX. candidate to nominate product additional before building are We

external potently receptor. target And strategy, an new target have that validation. gamma exciting the TIGIT is our immuno-oncology with So with EOS-XXX under Fc we demonstrated engage

been with another And exploring target. encouraging our are our plays receptor, tumor opportunities have some in potentially expand of the to We partnerships. there new role activity Adenosine an plans and in pathway strategic through development accelerate signals important immunosuppression microenvironment. adenosine

near new of ongoing the drugs overcome of forward other unplanned to clinical will look trials limitation the in inupadenant its in will call design over to properties Our And EOS-XXX Joe, Officer, concept Chief clinical the Joe detail. of future. Medical now class. inupadenant in the in I development discuss more both in the and we please. to to progress achieving the program of Lager, pass proof our

Joe Lager

the adenosine. last receptor high is differentiated next highly mechanism, key expressed minimal target tumor adenosine we'll cancer selective the of Unlike receptor despite AXAR, Thank inupadenant pembrolizumab inupadenant month. potential effector targets at therapeutic is could microenvironment. currently adenosine’s of antagonists several inhibition pathway an ASCO We're tumors We with improve pathway. against signaling like from in suppresses was our response providing monotherapy even the chemotherapy. that AXAR responses mediating selected inhibit portion well-tolerated a a this and responsible adenosine the with critical or in immune generation inupadenant, with conditions a expected inhibits the inupadenant antagonists, AXAR as Phase no anti-tumor AXAR of cell. study selectively concentrations high both which the evaluating at escalation Inupadenant AXAR cancer receptor the stage has were of are adenosine year. to based it combination of designed characterization which immune There to Inupadenant showed penetration on The are and is the therapeutic I'd has and with thought on properties. immune presenting response. Michel. The a potent off-target AXAR, prior therapies. potential barrier And index. you, antagonist, effects is dose current also X multiple limiting inhibit on update tumor of in was for highly the in adenosine to begin dose advanced for and immunosuppressive immunosuppressive and cells to pharmacologic safety adenosine critical block a concentrations therapeutic to blood-brain of unique at immune presented to summary which patients Xb/Xa We next a by reduce that effects AXAR microenvironment. results adenosine and AACR for with restore potently studies, design presence is an receptor our The then Phase in be the generations properties progress toxicity. and

daily, a dosing. These forward twice In adult for the patients approaches. in all multiple XX responses inhibition generated Phase to on distinct associated the advanced the given the pretreated clinical heavily focused which our four in in the with pretreated in durable benefit much have trial melanoma the when and And the a where this AXA as at ASCO cancers heavily on X/Xa resistant AXAR month excitement clinical a demonstrated seen biomarkers monotherapy partial results of metastatic next that presenting look across with program. finding of We're strong after advanced with and in for will the an multi-arm inupadenant doses in be tumor solid also signaling inhibitor with single resulted as that prostate the agent clinical rationale cohort shown monotherapy tumors, patient patients update evaluated addition AXAR full may we We've castrate-resistant with executing hours treatment be checkpoint currently in cancer. of expression with a We're patients at tested and antagonist. cohorts tumor there's enrolling in an receptor outcomes. study both combination

– castrate-resistant the metastatic two We cancer, castrate-resistant and monotherapy cohort one evaluating patients prostate combination with second in cohorts is in with pembrolizumab. have inupadenant

inhibitor combination breast evaluating cancer. cohort inupadenant triple patients combination in with is melanoma. third in evaluating in fourth pembrolizumab inupadenant with cohort in The The resistant negative with patients chemotherapy is with checkpoint

cancer. response now domain, immune modulatory treatment. biomarker tumor identify expressing benefit most to killing to programs process EOS-XXX, will two, AXAR dampen the cytokines into open achieve immune of AACR at of the single with blocking an One, depleting clinical pro-inflammatory partial optimal Dr. to responses, cell, agent significant and in the pembrolizumab engaging highest effects the We EOS-XXX as patients mechanism. trial signs with the melanoma potent a immune-mediated chemokine designed will provide enhance are antigen we treatment from in tumors. affinity down, anti-TIGIT data a den were one binding in-human clinical benefit receptor in immune confirmed activation to monotherapy overview therapeutic our Tregs slide continue note, T-cells. response, our from patients to with known a including with choose encouraging and escalation refractory I advanced that response likely integrate presented very release report promote and of in mechanisms. We potential antibody the mutant further TIGIT a the patients with pleased patient. Fc observed to stimulatory and functional portion to immune and three the month BRAF resulting of advanced Of our anti-tumor to that with approach presenting with solid EOS-XXX Mooter Last anti-tumor a clinical the of has cells of EOS-XXX label immunosuppressive driven FC dose cells, three, Van of X first receptor exhausted through Phase cells through multifaceted the through gamma combinations

a drugs We tested this non-lethal and also the consistent safety well-tolerated. doses with were of within other profile all generally observed class

a Treg engagement on responses strong data pursuing highly in Our EOS-XXX and and new as stronger EOS-XXX. our that robust with in robust for indicate FC development signs and a monotherapy early preliminary peripheral depletion on responses the checkpoint-resistant positive three these immune EOS-XXX coupled settings. receptor target results, Based efficacy the T-cells, we're clinical of a even checkpoint-naive activity time with and active biomarker gamma approaches potentially reinforcing CDX TIGIT hypothesis combination may biomarker data exhausted combination initial studies. positive demonstrated is drive with TIGIT about positive of These reduction

where to of benefit a improve We the as EOS-XXX patients. may the will patients but indicated in where of PD-X assess addition monotherapy, pembrolizumab inhibition EOS-XXX is combination with clinical

PD-LX squamous lung We will pembrolizumab combination and move line assess disease of next of where populations. specific safety the low non-small we'll EOS-XXX and the in both cancer, cell the heading and assess cancer trials high with cell into tumors PD-LX we'll then first solid first in

Chief planning planning evaluate patients EOS-XXX and of myeloma. these in to We're EOS-XXX including negative We and Matthew checkpoint in in in are solid cancer. evaluate combination inhibitor pancreatic plans other cancer, or with mid-XXXX our call and cancer Financial breast an relapsed for and IMID hand the melanoma over development are now studies refractory EOS-XXX with our continuing the start to I tumors, to triple gastric Officer. also inupadenant to Gall, combination clinical resistant multiple in

Matthew Gall

equivalent a net XX.X quarter attributable and expenses as quarter ended $XX.XX common publicly loss Michel of XXXX. We a were EOS-XXX, first was quarter XXXX. for million an cash results XX, was as trials net compared share Thanks, administrative compared current over compared position million the on like XXXX. and diluted XXXX XX, project development and closing This professional that of as for per of to and increase of based Joe. turn on March ended of and Research March headcount. XX a increased and XXXX. million XXXX XXXX costs a March I'll a the quarter to basic the XXX.X balance XXXX. this update primarily was to basic traded million the to The or quarter per XX, to XXXX cash the activities of of The now for $X.X to plan, I'd XXXX. was the increase the our inupadenant fees our as and provides $X.XX other X cash million first provide March the becoming net shareholders for company's remarks. The share as XXX.X brief back clinical General were of million financial XX, loss expenses to call diluted to March well for associated and ended into for runway for to XX.X headcount to increased for compared quarter first loss and as company. million due or with related X.X X.X primarily in of increase clinical due first quarter for million

Michel Detheux

Thank Matt. you,

As this and the improve to to mission forward progress, programs call two continuing cancer. are of on with advancing our clinical our people move ongoing make discovery outlined we efforts our with to lives

of in upcoming clinical to in June, inupadenant execution. continue the update With progress ASCO data we our

be anticipate both strengthen which our XX all on particularly immunology settings. on to we inupadenant position combination evaluate potential over your call checkpoint-naïve clinical establishing your immunosuppression of believe to for focused new that pivoted differentiated both to program EOS-XXX TIGIT plan the space, XX of resistant development EOS-XXX as outcomes checkpoint today’s the next patients, in of approaches understanding operator improve for and we and are will We interest. the for you have and the will cancers. both call to of and pipeline months EOS-XXX We cancer our our the to now of have kinds cancer cancer biology deep With to for and I’d attention ongoing the very back immunotherapy. we questions. Thank the continue the for development much like in turn

Operator

you, [Operator First is Chris Thank Sandler. from question of Raymond Piper speakers. Instructions]

Your line is now open.

Chris Raymond

Hey, guys. thanks

maybe should a a question us of think breast is indications expect to XXX. drug. melanoma, you frame that see just think we talked at update thinking of big now that there's I about you guess, just then we around slides we on there second you maybe some a provide that your I little that of what next would guys Can framed was looking through the and Thanks. program Can during more corporate be noted guess you I at I additional think maybe prostate guess – the we this appropriate be deck for And were in that. But on likely sort data were that you ASCO, one I your a SITC Just second noted have the under of maybe couple outside was talk call, there? bit? thinking venue. half AACR clarity, your and EOS-XXX. – evaluation deck. just And ASCO. also on also I just for questions And I you you on of for that should something triple-negative

Michel Detheux

important to start I'm the Joe And update in endometrial you than about biomarker and move the for cancer, and update to six in believe prostate, data now who the A the expansion in in to biopsies patient planning We consideration. important let the step go strategy. for disclosing the is do Chris, the additional the that detail additional XX to data about include our the under between be we’re monotherapy. continue will inupadenant benefit data I field inspections with level be the to combination for useful our forward What Hi, the consideration. data melanoma, result thank later collision be clinical stop I-O I potential indication; questions. clinical is next one for we with more taking are each of going and that and do appear that here explore for that our an PK/PD and data And in the turn year with and inupadenant program. on biopsy with will planning into related to following domestic disclosure discovery on to biomarker Joe expanding will under monotherapy could patients lung shipping would next indication will are will our XX indication strategy. a for and more

Joe Lager

are couple Chris, quite this considering that non-small Michel. a are solid lung as in, we other indications interested there cell indications cancer. for we are Thanks, program, tumor of

Michel we patients a involved are further As endometrial said extension. considering cancer we some two monotherapy our and both types doing cohort where are in additional

Chris Raymond

When be factors terms would tumor pancreatic cancers in guys types? can able think XXX, as about gating talking what's in that? – – other as I and these then Okay. of we're And a a gating on you've on make in follow-up about think gastric indications, to your targets. If heard you I I possible also I decision also prepared guys ask guess I remarks talk

Joe Lager

Yes.

study are provide we an I the we this evaluating we I mention that cancer on pancreatic opportunity did There later program update the and year. gastric say likely cancer development to would cancer. So designs. considering can are

Chris Raymond

you. Thank

Operator

SVB Daina of line Next Graybosch from is the question Leerink. of

is line now Your open.

Daina Graybosch

going for on Hi, follow-up the and thank help question. One the combination to about is and you and years TIGIT? six is I current months, make pancreatic now question to us you're rationale inupadenant evolved have decisions bit more a for for just your and looking still had your the or you this TIGIT, inhibitor, development your Daina. over whether the into This next could if the what they with plan, understand you AXA plan the forward purely you're wonder in considering

Michel Detheux

please. Joe,

Joe Lager

Thanks, Daina.

think program. we I are our the terms of plan, the your the TIGIT development in So EOS-XXX, and on focused rationale question – was for

you follow-up as if questions on to have I'm focus and there can So you going there well.

setting. developing non-small that cell cancer interest or first we to are have it did So earlier easily some compare the opportunity that our whether first-line to data can lung with in adjuvant provides cell lung cancer, a have non-small at competitors us. that with an type we potentially We setting setting report the faster for of always look has first-line adjuvant the to decided proceed been in more debate setting. us We the over and provide

competitors be This cancer, tumor as indication neck So to cancer we the potentially are therapy of should quite while. prioritized that. being in for they has opportunity us other cancer the there We indications benefit like we head have and to are is up us a feel anti-TIGIT been maybe not who as with an is where we there to similar patients. lung for are aggressive biology in Head ahead non-small types. and a that and quite catch cell think think that that I there pembrolizumab interesting adding neck to anticipate

able on We're So quite encouraged after tumor therapy think we're being the melanoma be other because show resistance quite we dose to in checkpoint seen we've PD-X saw interesting. melanoma. who those therapy also would we activity after enhanced indications. inhibitor in a And in inupadenant interested why escalation are the in in by reasons We're the that in PD-X. acquired long patients to with interested PD-X signal having resistant response had

target Seattle other of in with that show to Institute PD-X then setting. in activity have to that the is, collaborator antibodies really pre-clinical we could potential combination of and So that at that And in proof in we've a show setting the post-PD-X the patients is model for with a cancer with that than in additional of relevant Fred combination myeloma TIGIT combination looking data that the have a we benefit type at much immune generated you with see IMID. are Hutchinson an more these that potential concepts anti-TIGIT myeloma, benefit that with in

still it we of other a There early In in follow-up? with in has about been interesting the cancer is is historical considering, answered do pancreatic still type tumor there. our do to been see think very other adenosine It's has we and data for pancreatic the promising success rate if interesting low. there some that data, for that combination I've AXA recent do I'll challenging as think treat. But indications the the antagonist. we're something around be know quite could cancer. to tumor receptor in terms it's think continuing combination that or interested have stop particularly targets pathway but are where a It’s we yes, you any and question, your you

Daina Graybosch

very it follow-up adenosine topic like seeing if have seeing than us a us thank as you're you was could signature? maybe and your different helpful. I your That a can And And biomarkers, inupadenant. for you around have in seen? others signature. remind sounds And competitors be context you know on you developed biomarker very much. some something different what’s something that you remind can different what that's are, Maybe And

Joe Lager

a That's good Thanks. Yes. question.

adenosine, as we terms AXA evaluate So to NanoString signatures. and profiling RNA we also studies, program, potentially and as well doing EOS-XXX targets both immunohistochemistry are the on adenosine are so the in the gene within inupadenant our doing enzymes that immune biomarkers, various or for of in focusing receptor produce studies pathway, AXA cells

the of The to the seeing correlation [indiscernible] generating that patients. AXA team the challenging terms [indiscernible] AXA antibody abstract, It in it. ASCO turn the is think title receptor our assay tumors it clinical to took of is are indicated of in So by potential it effort a testing to difficult as for to and we we develop. IHC And of outcomes assay our to that cells AXA quite the or expressing and there quite bit able develop between receptor. target what be receptor a a then was expression

expression So AXAR a tumor we correlate the others, the as at within far as potential patient of as know, with haven't looked outcomes.

that receptor we're antagonist, are something under we may may So of be a why other antagonists seeing It identity because a have receptors selective be receptor selective, also that the target adenosine. unique very AXA other whereas here. number development are less of

you related at looking that that order the are looking that the to signature in signatures of will gene be that's terms and adenosine those the gene we at they're profiling in – gene in genes do on, our that. come reported up signatures, genes signature, myeloid in Mainly and that's that people what if we In in have system, been have that reported adenosine mainly cells it. monitoring put are to

guess of of is I a it a for concentration tumors way, have looking adenosine. higher So that

know is difficult a quite half-life. short may very Some adenosine has because it to measure,

So adenosine will with for it's be has and well whether there biopsy do our at adeno that is or a go and identify a tumor to challenging a and looking signature. target in a concentration not, gene we just as high

Daina Graybosch

very Very much. you helpful. Thank

Joe Lager

welcome. You're

Operator

of Rama of the Morgan. from Next question is Anupam line JP

Your line now is open.

Anupam Rama

about provide. EOS-XXX through the X saw or corporate so and in on the thanks and actually program congrats deck question for and Thanks you AXA deck also comment guys, a the new on so any much progress. all taking here, can tidbits I here , color much. flipping the formulation Phase entering Hey the was

Michel Detheux

status new of – X Joe Phase phase our please, anything can you formulation. new the update a of the about

Joe Lager

be I'd happy too.

initially a could the brought drug was We have dissolution formulation. terms we in formulation formulation of a the the freebase high think clinic that that of salt of properties at pH. now some we So into improve

are clinical formulation new are moving coming we a the trial coming – in start of months. couple salt and forward So with anticipating we'll that months that of

Anupam Rama

question. taking our for Thanks

Joe Lager

you. Thank

Operator

of of is Arthur question the He HC line Next Wainwright. from

Your open. line now is

Arthur He

Hey, taking the program. for good antagonist question had question. afternoon everyone thanks a my I regarding and in two adenosine

So us And monotherapy on for and more – duplet triplet, molecule give for first or color seemed focused that CRPC. your like in Arcus are the your on you even AstraZeneca indication? more combo on triplet a confidence guys the for could

Michel Detheux

identify Hi, yes indeed, mechanism believe antagonists that of for thanks doing to could a also adenosine us a the well, question specific receptor we action Stage us And – immunotherapy the in monotherapy And of the we population of this then prostate that of is of at dimensional get and better for to help cancer. the help that will such I adapted would are say end the monotherapy be to currently giving treatment. this more expansion. would X understanding

prostate have prostate allow pembrolizumab combination, explore, our cancer the additional with us would compared from added help strategy could For also and patient differentiate in significant has the for Joe, cancer? do to competitors. something It say you is the I add is to value. combination with to expectation to would treatment, program which this chemo which want free,

Joe Lager

you Thank so much Michel.

Arthur He

second my pipeline. Thanks for regarding And question that. the is

you guys in up pipeline later this into candidate can expect what I targeting past, from year? believe additional the announce adenosine So the we the

Michel Detheux

characterization to interest target, inupadenant the both new with is AXA. in which with target to our have combination we other also on never Based for refer and has of as indeed. has identified inupadenant, Yes, new be care excited and a cancer team go of a standard to [indiscernible] that this been research immunosuppression. used of pathway while described been for And

also move in And identification top clinical a said to on year that will the planning are planning pathway will of progress complimentary TIGIT AXA we of immunosuppression. and this to transition program, the report allow candidate. of On mechanisms in IND receptor forward adenosine are this make our to enabling of pipeline, I candidate add clinical continue We studies the end we programs programs and and as before thereafter. be to to adeno additional the

Arthur He

Thank you. Thank you for taking my question.

Michel Detheux

Welcome

Operator

Our is Wedbush the next question David Nierengarten line of Instructions] of [Operator from Securities.

now is line open. Your

David Nierengarten

tumors or to a thinking the bit to is one, – seen not where And AXA and here about on for see majority if going assay receptor I the have you on with just provides something Thanks. XXX%, see situation EOS-XXX? of your guess just your you seeing you expression, and but proprietary the how the you you research a I'm assay to guess we think go that assay Hi, in potentially hands then after express a your competitor about tumor, tumors XX% I'll your curious, can of edge when development. competition taking in two, so with follow-up or assay, your thanks your a for question focus the or how a results thinking receptor competitive Daina's, say, use protect could that. about question, if I are your

Michel Detheux

question. for thanks David, Hey the

As I on questions our was Chris related the been of to his also best say data extent former discuss this how receptor to to able would in we've antagonist. that the protection any application. by turns timing related to mentioned new, to protect patent And AXA biomarkers

at significant to robust large we used be scale. that will be when mentioned very As confident to able this use And be assay a with assay it’s the clinical are Joe challenge we'll to be been looked samples. that

later the far also We next give into so we data are assay we or still receptor and is additional described distraction a see data because say insight why never would additional adenosine in disclose year the year. us, been working making that reason on this I for antagonist

a percentage that participation, of to competitive like comments believe we it the turn and I be would to get advantage for iTeos terms additional and application the why explain to In Joe of will

Joe Lager

Michel. Thanks,

So data the we on continuing generate use of are to pathway.

the at tumor the the number receptor. looking are We expressing AXA within cells of

continuous a that's So variable.

tumor because been would there a types, is the cutoff types. the be to what considered we we're continuing and the There's considered the a by data different to in what So information say receptor this in that of such not have is to on out what different available what AXA has using lot high work IHC tumor would this to assay be low. and expression And develop. we're expression challenging interrogate

we've working at assays it on least in some we competitive types. and a different had has data lab doing these I head-start understanding because think a expression been our on there, that is internal but and advantage tumor So have

David Nierengarten

you. Thank Okay.

Operator

I'm at thank a great you today's in your conclude Everyone participating now conference. does showing questions This gentlemen, queue no program in day. you disconnect. further this Ladies and time. and have for the may

iTeos Therapeutics (ITOS) 14 May 212021 Q1 Earnings call transcript